EDDA Technology

EDDA Technology operates as a global provider of imaging-guided precision treatment solutions, with its headquarters in Princeton, New Jersey and subsidiaries in Shanghai and Suzhou, China. The company has developed the proprietary IQQA platform, which delivers computer-assisted solutions across the entire patient management cycle—from early detection and diagnosis through treatment planning, intra-operative navigation, and post-operative assessment.

Company Overview

Led by Dr. Jianzhong Qian as President and CEO, EDDA Technology pioneered the “fully quantitative, real-time interactive” approach to multimodality imaging analysis. The company maintains a dual presence in the United States and China through its subsidiaries: 医软信息科技（上海）有限公司 (YiRuan Information Technology Shanghai) and 医达极星医疗科技（苏州）有限公司 (EDDA JiXing Medical Technology Suzhou).

The IQQA platform represents the company’s core technological achievement, integrating advanced 3D imaging analytics with surgical robotics capabilities. This platform has been deployed in clinical settings with over 100,000 documented case applications, primarily supporting treatment of liver, kidney, and lung cancers.

Core Products

IQQA-Guide Surgical Navigation System

The flagship product, IQQA-Guide, provides intra-operative precision 3D navigation for surgical procedures involving thoracic, abdominal, and pelvic soft organs. The system extracts fully quantified, patient-specific anatomic models from multimodality images, enabling physicians to visualize organ surfaces and reference anatomies of interest in real-time 3D during surgery. Clinical studies have demonstrated that IQQA-Guide may reduce the need for intra-operative CT scans during image-guided surgical procedures.

IQQA-Guide received FDA clearance in November 2015 and subsequently obtained NMPA approval in China in January 2020, also qualifying for the National Medical Device Innovation “Green Channel” expedited review pathway.

IQQA-BodyImaging

This software platform provides precision 3D imaging analytics for treatment planning and assessment, supporting open surgery, interventional procedures, minimally invasive surgery, and robotic surgery. IQQA-BodyImaging has been widely adopted for managing liver, kidney, and lung cancer cases, with clinical data indicating significant time savings and improved patient care outcomes.

eQMR System

The Real-time Interactive Quantitative Mixed Reality (eQMR) system represents EDDA’s advancement into augmented reality surgical guidance, combining mixed reality visualization with the company’s quantitative imaging analytics capabilities.

Technology & Innovation

Built to provide fully quantitative real-time imaging guidance, EDDA Technology’s IQQA platform has supported over 100,000 clinical cases across liver, kidney, and lung cancer procedures.

The IQQA platform distinguishes itself through several technical capabilities:

• Multimodality Image Fusion: Integration of CT, MRI, and other imaging modalities into unified 3D anatomic models
• Real-time Navigation: On-the-fly 3D guidance during surgical procedures with quantitative anatomical referencing
• Cloud-Based Services: OnDemand cloud platform enabling remote access to IQQA applications for treatment planning and assessment
• Full Cycle Coverage: Pre-operative planning, intra-operative navigation and monitoring, and post-operative assessment within a single platform ecosystem

The company holds multiple registrations and clearances from both the NMPA in China and the FDA in the United States.

Market Presence

EDDA Technology serves the precision medicine market across multiple geographies, with particular strength in cancer treatment applications. The company’s cloud-based OnDemand services extend its reach to healthcare facilities that may not have on-premises installation capabilities.

The company has established clinical partnerships and exhibited at major medical imaging conferences including RSNA (Radiological Society of North America), where it has showcased advances in the IQQA platform.

Key Milestones

• 2015-11: FDA clearance for IQQA-Guide intra-operative precision 3D navigation system
• 2020-01: NMPA approval for puncture surgical navigation device (IQQA-Guide); National Innovation “Green Channel” qualification
• Ongoing: Over 100,000 clinical case applications of IQQA precision surgical planning platform

Frequently Asked Questions

What is the IQQA platform?

The IQQA platform is EDDA Technology’s proprietary technology suite that provides fully quantitative, real-time interactive imaging analysis and surgical guidance. It covers the complete treatment cycle including pre-operative planning, intra-operative navigation, and post-operative assessment for cancer and other surgical procedures.

What regulatory approvals does EDDA Technology hold?

EDDA Technology has received FDA clearance in the United States for multiple products including IQQA-Guide and IQQA-BodyImaging. In China, the company has obtained NMPA approval for its puncture surgical navigation device, with the product qualifying for the national innovation “green channel” expedited review process.

Where is EDDA Technology headquartered?

EDDA Technology maintains its global headquarters in Princeton, New Jersey, USA, with Chinese subsidiaries located in Shanghai and Suzhou.